EOJOAM
RXRX icon

E. Ohman J:or Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

E. Ohman J:or Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,482
Closed -$73.8K – 428
2023
Q4 		$73.8K Buy
7,482
+582
+8% +$4.15K ﹤0.01% 409
2023
Q3 		$52.8K Buy
+6,900
New +$68.8K ﹤0.01% 416

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

E. Ohman J:or Asset Management's RXRX Position: Q1 2024 in Review

E. Ohman J:or Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 7,482 shares — an estimated $73.8K sold.

E. Ohman J:or Asset Management first reported a position in RXRX in Q3 2023 and held it in 2 quarters. The position peaked at $73.8K in Q4 2023. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

  • E. Ohman J:or Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • E. Ohman J:or Asset Management sold 7,482 Recursion Pharmaceuticals shares in Q1 2024, an estimated $73.8K.
  • E. Ohman J:or Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • E. Ohman J:or Asset Management's Recursion Pharmaceuticals position peaked at $73.8K in Q4 2023.
  • 249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on E. Ohman J:or Asset Management's 13F filing for Q1 2024, filed 14 May 2024.